Skip to main content

Table 3 Prospective associations of plasma tran-fatty acids with risk of cardiovascular diseases mortality (n = 1456)

From: Plasma trans-fatty acids levels and mortality: a cohort study based on 1999–2000 National Health and Nutrition Examination Survey (NHANES)

 

Events (n/%)

Number at risk (Person-years)

Model 1

Model 2

Model 3

Hazard Ratio

(95% CI)

P value

Hazard Ratio

(95% CI)

P value

Hazard Ratio

(95% CI)

P value

Elaidic acid (C18:1 t9), μM

Per 10 units increase

39(2.7)

1456 (16034)

1.14(1.02–1.27)

0.021

1.12(0.95–1.33)

0.180

1.64(1.07–2.50)

0.023

Per sd increase

1.33(1.04–1.69)

0.021

1.29(0.89–1.88)

0.180

2.96(1.16–7.55)

0.023

Quartile (Range, μM)

 Quartile 1 (4.5–23.4)

6(1.7)

363(3974)

0.66(0.24–1.81)

0.415

1.01(0.34–3.01)

0.983

0.99(0.33–3.04)

0.993

 Quartile 2 (23.5–32.3)

10(2.8)

363(4078)

Reference

 

Reference

 

Reference

 

 Quartile 3 (32.4–44.7)

11(3.0)

366(4048)

1.34(0.56–3.18)

0.512

1.31(0.53–3.23)

0.562

1.44(0.56–3.68)

0.447

 Quartile 4 (44.9–238)

12(3.3)

364(3934)

1.36(0.58–3.18)

0.473

1.34(0.48–3.71)

0.572

1.67(0.50–5.61)

0.404

Vaccenic acid (C18:1 t11), μM

Per 10 units increase

39(2.7)

1456 (16034)

1.08(0.98–1.18)

0.135

1.04(0.90–1.20)

0.621

0.75(0.52–1.09)

0.134

Per sd increase

1.20(0.94–1.52)

0.135

1.10(0.76–1.58)

0.621

0.49(0.20–1.24)

0.134

Quartile (Range, μM)

 Quartile 1 (4.45–27.9)

10(2.7)

364(3997)

1.19(0.47–3.00)

0.720

1.35(0.51–3.60)

0.546

1.39(0.51–3.79)

0.516

 Quartile 2 (27.9–37.5)

8(2.2)

363(4019)

Reference

 

Reference

 

Reference

 

 Quartile 3 (37.6–49.7)

11(3.0)

364(4036)

1.36(0.55–3.39)

0.509

1.21(0.46–3.18)

0.695

1.22(0.45–3.28)

0.695

 Quartile 4 (49.8–313)

10(2.7)

365(3982)

1.35(0.53–3.42)

0.529

1.10(0.37–3.24)

0.864

0.77(0.19–3.11)

0.711

Palmitelaidic acid (C16:1 t9), μM

Per unit increase

39(2.7)

1456 (16034)

1.05(0.97–1.13)

0.243

1.02(0.92–1.14)

0.707

1.01(0.86–1.18)

0.946

Per sd increase

1.19(0.89–1.58)

0.243

1.08(0.71–1.65)

0.707

1.02(0.55–1.88)

0.946

Quartile (Range, μM)

 Quartile 1 (1.1–5.1)

6(1.7)

363(3989)

0.65(0.24–1.74)

0.388

0.80(0.27–2.31)

0.675

0.84(0.28–2.52)

0.755

 Quartile 2 (5.1–6.8)

12(3.3)

365(4060)

Reference

 

Reference

 

Reference

 

 Quartile 3 (6.9–9.4)

8(2.2)

364(4057)

0.61(0.25–1.49)

0.280

0.54(0.21–1.38)

0.202

0.62(0.24–1.63)

0.334

 Quartile 4 (9.4–33.1)

13(3.6)

364(3928)

1.17(0.54–2.58)

0.688

1.09(0.39–3.03)

0.866

1.01(0.32–3.20)

0.987

Linolelaidic acid (C18:2 t9, 12), μM

Per unit increase

39(2.7)

1456 (16034)

1.04(0.85–1.27)

0.720

0.94(0.69–1.28)

0.705

0.74(0.50–1.11)

0.144

Per sd increase

1.06(0.77–1.46)

0.720

0.91(0.55–1.49)

0.705

0.62(0.33–1.17)

0.144

Quartile (Range, μM)

 Quartile 1 (0.7–2.0)

9(2.5)

364(3975)

1.18(0.47–2.99)

0.720

1.08(0.40–2.87)

0.880

1.19(0.44–3.24)

0.732

 Quartile 2 (2.0–2.7)

9(2.5)

363(4004)

Reference

 

Reference

 

Reference

 

 Quartile 3 (2.7–3.7)

10(2.7)

365(4057)

1.75(0.70–4.37)

0.230

1.48(0.55–3.95)

0.434

1.35(0.50–3.65)

0.553

 Quartile 4 (3.7–13.4)

11(3.0)

364(3998)

1.65(0.68–4.03)

0.271

1.31(0.47–3.65)

0.608

0.89(0.28–2.84)

0.844

  1. Model 1: adjusted for age, gender at baseline
  2. Model 2: further adjusted for race, body mass index, systolic blood pressure, diastolic blood pressure, fasting plasma glucose, triglyceride, total cholesterol, high density lipoprotein, uric acid, estimation glomerular filtration rate, alcohol use, smoking, and self-reported cardiovascular diseases history at baseline
  3. Model 3: further adjusted for other trans-fatty acid subtypes
Back to article page

Lipids in Health and Disease

ISSN: 1476-511X